Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and...

Tirzepatide has demonstrated good efficacy and safety in the management of type 2 diabetes (T2D) in clinical trials. As the importance of early intensive intervention is known, the tirzepatide benefit for early glycemic and weight management (T-BEAT) study investigated the real-world effectiveness of tirzepatide in participants with early stage T2D in Japan.

This in-progress, noninterventional, multicenter, observational study assesses the glycemic control of tirzepatide (5-15 mg once weekly) or oral semaglutide (7-14 mg once daily) in participants with T2D who were naive to oral antidiabetes drugs (OADs) (diet and exercise only) or received OAD monotherapy, excluding oral semaglutide. The primary endpoint is the mean change in glycated hemoglobin (HbA1c) from baseline after up to 12 months of treatment. Patient-reported treatment satisfaction and other secondary endpoints are also being investigated. Baseline characteristics of the participants are reported.

In the tirzepatide group (N = 290), mean participant age was 55.2 (standard deviation [SD] 13.4) years, 45.2% were female, and the mean body weight, body mass index (BMI), and baseline HbA1c were 79.6 (SD 13.2) kg, 29.3 (SD 3.5) kg/m², and 8.0% (SD 0.8), respectively. In the oral semaglutide group (N = 279), the mean participant age was 58.8 (SD 13.3) years, 35.5% were female, and the mean body weight, BMI, and baseline HbA1c were 77.2 (SD 12.3) kg, 28.2 (SD 3.0) kg/m², and 7.8% (SD 0.7), respectively. In both groups, dyslipidemia was the most common comorbidity (62.1% and 67.7%); 40.7% and 38.0% of participants, respectively, concomitantly used OADs; and sodium glucose co-transporter 2 inhibitors and biguanides were the most common OADs.

The T-BEAT study assesses the real-world effectiveness of tirzepatide over a 12-month treatment period in participants with early stage T2D. This study's results are expected to provide valuable information to physicians, enabling them to make informed decisions in routine clinical practice.